Literature DB >> 6149801

Vecuronium in renal failure.

D R Bevan, F Donati, H Gyasi, A Williams.   

Abstract

Neuromuscular blockade during surgery was provided with vecuronium in 24 adult patients in end-stage renal failure and in 21 normal patients who served as controls. Dose response curves were constructed which showed that the effective doses required to produce 50, 90 and 95 per cent neuromuscular blockade in patients with renal failure were 27.5, 43 and 49 micrograms X kg-1 respectively. These were not significantly different from the doses of 31, 49 and 57 micrograms X kg-1 in the normal patients. Repeated small doses of 0.01 mg X kg-1 had a significantly longer duration of action and were associated with some cumulation in the renal failure group. Recovery from the block occurred rapidly after neostigmine, was no different in renal failure and was not associated with recurarization. It is concluded that, when given to subjects in renal failure, vecuronium offers advantages over established agents such as shorter duration of action and easy reversibility.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149801     DOI: 10.1007/bf03009532

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  18 in total

1.  The emergence of ORG NC 45, 1- [2 beta,3 alpha,5 alpha,16 beta,17 beta)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series.

Authors:  D S Savage; T Sleigh; I Carlyle
Journal:  Br J Anaesth       Date:  1980       Impact factor: 9.166

2.  Renal failure and postoperative respiratory failure: recurarization?

Authors:  R D Miller; D J Cullen
Journal:  Br J Anaesth       Date:  1976-03       Impact factor: 9.166

3.  Clinical experience with ORG NC45 (norcuron) as the sole muscle relaxant.

Authors:  A Williams; H Gyasi; C Melloni; D R Bevan
Journal:  Can Anaesth Soc J       Date:  1982-11

4.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

Authors:  M R Fahey; R B Morris; R D Miller; T L Nguyen; R A Upton
Journal:  Br J Anaesth       Date:  1981-10       Impact factor: 9.166

5.  Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults.

Authors:  D M Fisher; C O'Keeffe; D R Stanski; R Cronnelly; R D Miller; G A Gregory
Journal:  Anesthesiology       Date:  1982-09       Impact factor: 7.892

6.  The pharmacokinetics of d-tubocurarine in man with and without renal failure.

Authors:  R D Miller; R S Matteo; L Z Benet; Y J Sohn
Journal:  J Pharmacol Exp Ther       Date:  1977-07       Impact factor: 4.030

7.  Use of atracurium in patients with no renal function.

Authors:  J M Hunter; R S Jones; J E Utting
Journal:  Br J Anaesth       Date:  1982-12       Impact factor: 9.166

8.  The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

9.  Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat.

Authors:  I G Marshall; A J Gibb; N N Durant
Journal:  Br J Anaesth       Date:  1983-08       Impact factor: 9.166

10.  Antagonism of pancuronium in renal failure: no recurarization.

Authors:  D R Bevan; D Archer; F Donati; A Ferguson; B D Higgs
Journal:  Br J Anaesth       Date:  1982-01       Impact factor: 9.166

View more
  8 in total

1.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

2.  Vecuronium is more potent in Montreal than in Paris.

Authors:  P Fiset; F Donati; P Balendran; C Meistelman; E Lira; D R Bevan
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

3.  Does vecuronium accumulate in the renal transplant patient?

Authors:  M A Starsnic; M E Goldberg; D E Ritter; A T Marr; M Sosis; G E Larijani
Journal:  Can J Anaesth       Date:  1989-01       Impact factor: 5.063

Review 4.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Secondary hyperparathyroidism shortens the action of vecuronium in patients with chronic renal failure.

Authors:  K Takita; Y Goda; O Kemmotsu; H Mashio; A Okuyama; Y Ito; H Sakamoto; H Kawahigashi
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

Review 6.  The use of muscle relaxants in the intensive care unit.

Authors:  M D Sharpe
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

7.  Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine.

Authors:  A Sidi; R F Kaplan; R F Davis
Journal:  Can J Anaesth       Date:  1990-07       Impact factor: 5.063

8.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis.

Authors:  C Beauvoir; P Peray; J P Daures; J L Peschaud; F D'Athis
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.